These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8875978)

  • 1. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY; Xia W; Shao R; Hung MC
    Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT; Yu D; Hung MC
    Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
    Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H; Qin H; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of E1A gene on the growth and chemosensitivity of transplantation tumor of nude mice].
    Wang XL; Qian XL; Zhao QZ; Xu ZG; Tang PZ
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Dec; 38(6):409-12. PubMed ID: 15040099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer therapy utilizing an adenoviral vector expressing only E1A.
    Hubberstey AV; Pavliv M; Parks RJ
    Cancer Gene Ther; 2002 Apr; 9(4):321-9. PubMed ID: 11960282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu.
    Chen H; Yu D; Chinnadurai G; Karunagaran D; Hung MC
    Oncogene; 1997 Apr; 14(16):1965-71. PubMed ID: 9150363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism.
    Frisch SM; Dolter KE
    Cancer Res; 1995 Dec; 55(23):5551-5. PubMed ID: 7585633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
    Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
    Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
    Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma].
    Wang XL; Qian XL; Zhao QZ; Xu ZG; Tang PZ
    Ai Zheng; 2003 Nov; 22(11):1140-6. PubMed ID: 14613640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.